Evidence map›Paper›PMID 28233275›Full record

ReviewDrugs2017

Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.

Pieter Hindryckx, Gregor Novak, Niels Vande Casteele, Reena Khanna, Debby Laukens, Vipul Jairath, Brian G Feagan

Erratum issuedAbstract readReview
PubMed Publisher
In one paragraph

Review in Drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 27 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 4 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 4 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Reversal of anti-drug antibodies against tumor necrosis factor inhibitors with addition of immunomodulators: A systematic review and meta-analysis.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2020
    Pooled it
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Therapeutic Antibodies: An Overview.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Pieter HindryckxRobarts Clinical Trials, University of Western Ontario, London, ON, Canada.
Gregor NovakRobarts Clinical Trials, University of Western Ontario, London, ON, Canada.
Niels Vande CasteeleRobarts Clinical Trials, University of Western Ontario, London, ON, Canada.
Reena KhannaRobarts Clinical Trials, University of Western Ontario, London, ON, Canada.
Debby LaukensDepartment of Gastroenterology, University of Ghent, Ghent, Belgium.
Vipul JairathRobarts Clinical Trials, University of Western Ontario, London, ON, Canada.
Brian G FeaganRobarts Clinical Trials, University of Western Ontario, London, ON, Canada. brian.feagan@robartsinc.com.
Robarts Clinical Trials · CAWestern University · CALjubljana University Medical Centre · SIUniversity of California, San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The introduction of biologic therapy has revolutionized the treatment of inflammatory bowel disease (IBD). However, like all therapeutic proteins, monoclonal antibodies have immunogenic potential which is influenced by multiple drug- and patient-related factors. The reported incidence of anti-drug antibodies (ADAs) towards biologic drugs in IBD varies greatly in the literature and depends not only on differences in sensitization but also on the assay methodology and the timepoint of measurement. Sensitization with formation of ADAs is associated with an increased risk of infusion reactions, accelerated drug clearance, and a loss of response (LOR) to drug. Recently, a greater understanding of the pharmacokinetics of therapeutic antibodies has led to the development of new strategies to reduce immunogenicity and more efficient use of these drugs. These preventive strategies include regular scheduled dosing with maintenance of stable therapeutic trough drug concentrations, and co-administration of an immunosuppressive. Sub-therapeutic drug concentrations with low levels of ADAs can generally be overcome with dose escalation, whereas the presence of high concentrations of ADAs requires a switch to another therapeutic agent.

Indexed as

AnimalsAntibodiesAntibodies, Anti-IdiotypicHumansImmunosuppressive AgentsInflammatory Bowel DiseasesIntegrinsInterleukinsTumor Necrosis Factor InhibitorsTumor Necrosis FactorsAntibodiesAntibodies, Anti-IdiotypicImmunosuppressive AgentsIntegrinsInterleukinsTumor Necrosis Factor InhibitorsTumor Necrosis Factors

Identifiers

PMID28233275
OpenAlexW2589910009

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.